Diuretic peptide conjugate

Details Diuretic peptide conjugate Diuretic peptide conjugate

2007-07-17

2007-07-17

Housel, James C. (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S326000, C530S327000, C530S328000

Reexamination Certificate

active

09882291

ABSTRACT:
Disclosed are a variety of peptide conjugates represented by the following general formula:in-line-formulae description="In-line Formulae" end="lead"?R1-Z-X-Z′-R2in-line-formulae description="In-line Formulae" end="tail"?including methods of making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.

REFERENCES:
patent: 5688772 (1997-11-01), Estrada et al.
patent: 5837809 (1998-11-01), Grandy et al.
patent: 5840696 (1998-11-01), Lippton
patent: 6025326 (2000-02-01), Steinberg et al.
patent: 6156754 (2000-12-01), Lerchen et al.
patent: 6228840 (2001-05-01), Wei et al.
patent: 6387628 (2002-05-01), Little et al.
patent: WO 99/44627 (1999-09-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO 01/98324 (2001-12-01), None
patent: WO 02/26412 (2002-04-01), None
Dooley et al., “Binding and In Vitro Activities of Peptides with High Affinity for the Nociceptin/Orphanin FQ REceptor, ORL1,” J. Pharmacol. Exp. Ther. 283: 735-741 (1997).
D. Kapusta, et al. “Diuretic And Antinatriuretic Responses Produced By The Endogenous Opioid-like Peptide, Nociceptin (Orphanin FQ)”, Life Sciences, 60: PL15-21, 1997.
D.R. Kapusta, et al. “Central Administration Of |Phe 1Ψ (CH 2- NH)Gly 2| Nociceptin (1-13)-NH 2 And Orphanin FQ/Nociceptin (OFQ/N) Produce Similar Cardiovascular And Renal Responses In Conscious Rats”, J. Pharmacol. Exp. Therap. 289:173-180, 1999.
Daniel R. Kapusta, et al. “Cardiovascular And Renal Responses Produced By Central Orphanin FQ/Nociceptin Occur Independent Of Renal Nerves”, Am. J. Physiol., 277:R987-R995, 1999.
D.R. Kapusta “Neurohumoral Effects Of Orphanin FQ/Nociceptin: Relevance To Cardiovascular And Renal Funtion”, Peptides, 21:1081-1099, 2000.
D.R. Kapusta, et al. “Role Of The Renal Nerves In MediatingThe Renal Excretory Responses Produced By Central Administration Of The Opioid-Like Peptide, Nociceptin, In Conscious Rats”, FASEB. J., 12:A364, 1998.
D.R. Kapusta, et al. “Central Nociceptin Produces Biphasic Changes In Urine Flow Rate In Conscious Rats Via ADH Dependent And Independent Mechanisms”, Dept. Pharmacol. LSU Medical Center, New Orleans, LA 70112, and Phoenix Pharmaceuticals, Mountain View, CA 94043, FASEB J., 13:A457, 1999.
D.R. Kapusta, et al., “Nociceptin/Orphanin FQ Modulates The Cardiovascular And Renal Responses To Stress Differently Conscious Spontaneously Hypertensive Rats”, FASEB J., 15:A1143, 2001.
D.R. Kapusta, et al. “Renal Responses To Central Administration Of Nociceptin (Orphanin FQ), A Novel Endogenous Opioid-Like Peptide”, J. Amer. Soc. Nephrol. 7(9):1536, 1996.
D.R. Kapusta, et al. “Interaction Of Central mu Opioid And Nociceptin Systems In The Regulation Of Renal Excretory Function”, FASEB J. 11:A250, 1997.
D.R. Kapusta, et al. “Central Administration Of A Proposed Nociceptin Receptor Antagonist Produces Nociceptin-Like Cardiovascular And Renal Responses”, J.A.S.N. 9:308A, 1998.
L.A. Dayan, et al. “Central Injection Of Ro 64-6198, A Synthetic ORL1 Agonist, Produces Profound Nociceptin-Like Effects On Kidney Function And Feeding, But Not Cardiovascular Function”, FASEB J. 15:A1143, 2001.
Velga A. Kenigs, et al. “[Nphe 1] Nociceptin(1-13)NH2 Antagonizes The Cardiovascular Responses To Peripheral, But Not Central Administration Of Nociceptin/orphanin FQ In Conscious Rats”, FASEB J. 15:A1142, 2001.
Lapalu et al. “Comparison of the Structure-Activity Relationships of Nociceptin and Dynorphin A Using Chimeric Peptides,”FEBS Letters, 417(3):333-336 (1997).
Meunier et al. “The Nociceptin (ORL1) Receptor: Molecular Cloning and Functional Architecture,”Peptides21(7):893-900 (2000).
Rizzi et al. “Pharmacological Characterization of the Novel Nociceptin/Orphanin FQ Receptor Ligand, ZP120: In Vitro and In Vivo Studies in Mice,”British J. Pharmacol.137:369-374 (2002).

Affiliated with

Also associated with

Rating

Diuretic peptide conjugate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diuretic peptide conjugate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diuretic peptide conjugate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3778692